Contents
In line with its mission, the Editorial Board of MedTvoiLokony makes every effort to provide reliable medical content supported by the latest scientific knowledge. The additional flag “Checked Content” indicates that the article has been reviewed by or written directly by a physician. This two-step verification: a medical journalist and a doctor allows us to provide the highest quality content in line with current medical knowledge.
Our commitment in this area has been appreciated, among others, by by the Association of Journalists for Health, which awarded the Editorial Board of MedTvoiLokony with the honorary title of the Great Educator.
According to “Dziennik Zachodni”, the Excalate4CoV consortium, financed by the European Union, has selected another drug that may be effective in the fight against COVID-19. It could be used to treat people with mild coronavirus infection. Will raloxifene be used to treat COVID-19?
Scientists around the world are still looking for effective drugs to fight COVID-19. WHO conducts extensive research into the most promising therapies. Now another contestant may enter the game – a drug called raloxifene. It is a generic drug approved for the treatment of osteoporosis, which may also prove effective in the treatment of patients with mild COVID-19.
The Excalate4CoV consortium, which is funded by the EU, has tested over 400 data sheets using supercomputers. drug substance molecules and grouped them according to their effectiveness in the fight against coronavirus. Initially 7 thousand. molecules that were then tested in-vitro. Among these particles is raloxifene, which has been described as “promising” in activity.
There are currently no clinical trials to support the effectiveness of raloxifene in fighting COVID-19. Misuse of this medication may be hazardous to your health.
According to the authors of the study, the drug is intended for the treatment of osteoporosis could effectively block virus replication in cells, thus preventing the development of the disease. According to scientists, the advantages of this drug are good patient tolerance, safety and a tested toxicological profile.
The editorial board recommends:
- The European Medicines Agency approves remdesivir for the treatment of COVID-19
- “Antibody cocktail” against COVID-19 tested on humans in the USA
- Prof. Simon: The epidemic will continue until we find a vaccine and drugs
Raloxifene has a long way to go before it becomes recognized as a drug that helps fight the mild form of COVID-19 in patients. Excalate4CoV will discuss with the European Medicines Agency on how to continue clinical trials to evaluate its new potential use.
– Today we need science more than ever. Since January, we have been mobilizing all our efforts to support research and innovation actors in their respective fields to find solutions and stop the virus. That is why we donated EUR 4 million to Exscalate3CoV to fund research and I am delighted with the promising results they have achieved, said Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education and Youth, quoted by Western Journal.
Also read:
- The United States is not coping with the coronavirus epidemic. What mistakes did they make?
- Virus reproduction rate in Poland. The ministry provides official data
- An epidemic in Poland. What do we know about it from the perspective of the last three months?
How are you doing during the COVID-19 pandemic in Poland? Share your story with us. write on [email protected]